Proteomic Analysis Identified DJ-1 as a Cisplatin Resistant Marker in Non-Small Cell Lung Cancer

International Journal of Molecular Sciences

Hua-Zong Zeng⁴  Yi-Qing Qu²  Wen-Jun Zhang¹  Bing Xiu¹  An-Mei Deng³ 

[1] Central Laboratory, Tongji Hospital of Tongji University, Tongji University, Shanghai 200065, China; E-Mails:;Department of Respiratory Medicine, Qilu Hospital, Shandong University, Jinan 250012, China; E-Mail:;Laboratory Diagnostics, Shanghai Changhai Hospital, Shanghai 200003, China;School of Life Sciences and Technology, Tongji University, Shanghai 200092, China; E-Mail:

关键词: non-small lung cancer;    cisplatin;    resistance;    DJ-1;    proteomics;   

DOI  :  10.3390/ijms12063489

来源: mdpi

【 摘 要 】

The aim of study is to identify cisplatin-resistance associated biomarkers for non-small cell lung cancers (NSCLC). We use two-dimensional electrophoresis (2-DE) combined with MALDI-TOF mass spectrometry to compare the proteome between lung cancer cell line A549 and its cisplatin-resistant subline A549/DDP. Nine cisplatin resistance-related proteins were identified, and DJ-1, one of the differently expressed proteins, was selected for further validation and evaluation. Immunohistochemical results demonstrated that high expression level of DJ-1 was associated with cisplatin resistance and a predictor for poor prognosis in 67 locally advanced NSCLC patients. Furthermore, in vitro results showed that silencing DJ-1 increased the proliferation inhibitory effect of cisplatin to A549/DDP cells. In conclusion, DJ-1 might play an important role in the resistibility to cisplatin, and it could also act as a novel candidate biomarker for predicting the response of NSCLC patients to cisplatin-based chemotherapy.

【 授权许可】

CC BY   
© 2011 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.